Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc is advancing its pipeline of innovative therapies aimed at addressing inherited retinal diseases (IRDs) and other retinal disorders, showcasing significant patient-reported improvements in vision and functional outcomes. The company has experienced a notable increase in general and administrative expenses, indicating a commitment to scaling operations in alignment with regulatory progress and clinical efficacy data that reflects a substantial patient benefit and sustained visual improvements out to 18 months. With the European Medicines Agency (EMA) suggesting an accelerated regulatory pathway due to positive treatment outcomes, Opus Genetics stands to benefit from heightened visibility and potential market readiness.

Bears say

Opus Genetics has reported a decrease in R&D expenses for the recent quarter, amounting to $6.4 million, down from $9.0 million the previous year, indicating possible challenges in funding its developmental pipeline. The company has faced substantial losses since its inception, raising concerns about its financial sustainability and ability to attract further investment. Additionally, increasing market competition from emerging therapies that target similar indications poses a significant risk to Opus's market penetration and pricing strategy, further exacerbating its negative financial outlook.

Opus Genetics (IRD) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.